GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Loans Receivable

Entheon Biomedical (XCNQ:ENBI) Loans Receivable : C$0.00 Mil (As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Loans Receivable?

Entheon Biomedical's Loans Receivable for the quarter that ended in Feb. 2024 was C$0.00 Mil.


Entheon Biomedical Loans Receivable Historical Data

The historical data trend for Entheon Biomedical's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Loans Receivable Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entheon Biomedical Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Entheon Biomedical Loans Receivable Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.
Executives
Brian Jahns Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines